Xencor (NASDAQ:XNCR) Issues Quarterly Earnings Results, Beats Estimates By $0.19 EPS

Xencor (NASDAQ:XNCR) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.19, Zacks reports. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The firm had revenue of $52.79 million during the quarter, compared to the consensus estimate of $17.14 million.

Xencor Stock Up 4.2 %

Shares of Xencor stock opened at $14.98 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. Xencor has a 1-year low of $14.18 and a 1-year high of $27.24. The business has a 50-day moving average of $19.79 and a 200-day moving average of $20.68. The company has a market capitalization of $1.05 billion, a PE ratio of -4.68 and a beta of 0.70.

Insider Activity at Xencor

In related news, Director Alan Bruce Montgomery sold 13,301 shares of Xencor stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $27.03, for a total value of $359,526.03. Following the completion of the sale, the director now owns 9,140 shares in the company, valued at approximately $247,054.20. The trade was a 59.27 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 5.23% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

XNCR has been the subject of several analyst reports. Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $20.00 to $30.00 in a research note on Monday, December 2nd. StockNews.com cut shares of Xencor from a “hold” rating to a “sell” rating in a research note on Wednesday. Wells Fargo & Company initiated coverage on shares of Xencor in a research note on Thursday, December 12th. They set an “overweight” rating and a $37.00 price target on the stock. BMO Capital Markets restated an “outperform” rating and issued a $34.00 price objective (up previously from $32.00) on shares of Xencor in a research report on Friday, November 8th. Finally, JPMorgan Chase & Co. boosted their target price on Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $34.88.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.